Format

Send to

Choose Destination

See 1 citation found by title matching your search:

CNS Oncol. 2014 Jul;3(4):257-65. doi: 10.2217/cns.14.29.

Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.

Author information

1
Center for Translational Neuro-Oncology, Department of Neurosciences, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.

Abstract

AIMS:

We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.

PATIENTS & METHODS:

Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).

RESULTS:

We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.

CONCLUSION:

The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.

KEYWORDS:

alternative regimens; chemotherapy; glioblastoma; glioma temodar; safety; temozolomide

PMID:
25286037
PMCID:
PMC4214215
DOI:
10.2217/cns.14.29
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center